128 related articles for article (PubMed ID: 10616507)
1. Preoperative ATG bolus treatment increase CsA sensitivity of peripheral blood lymphocytes (PBLS) in renal transplant patients.
Abudher MN; Moorhead JF; Fernando ON; Varghese Z
Transplant Proc; 1999 Dec; 31(8):3361-4. PubMed ID: 10616507
[No Abstract] [Full Text] [Related]
2. Induction therapy with bolus ATG increases cyclosporine sensitivity in renal transplant recipients.
Varghese Z; Abudher MN; Fernando ON; Moorhead JF
Transplant Proc; 2001 May; 33(3):2251-3. PubMed ID: 11377518
[No Abstract] [Full Text] [Related]
3. Intraoperative T-cell depletion prior to completion of anastomoses by high-dose single ATG bolus as a new approach to improve long-term results after kidney transplantation.
Kaden J; May G; Strobelt V; Groth J; Müller P
Transplant Proc; 1997; 29(1-2):344-7. PubMed ID: 9123032
[No Abstract] [Full Text] [Related]
4. Short and long-term results after pretransplant high-dose single ATG-fresenius bolus in cadaveric kidney transplantation.
Kaden J; Strobelt V; May G
Transplant Proc; 1998 Dec; 30(8):4011-4. PubMed ID: 9865279
[No Abstract] [Full Text] [Related]
5. Experience with azathioprine withdrawal after simultaneous kidney-pancreas transplantation.
Stratta RJ
Transplant Proc; 1998 Jun; 30(4):1353-4. PubMed ID: 9636550
[No Abstract] [Full Text] [Related]
6. Intraoperative high-dose anti-T-lymphocyte globulin bolus in addition to triple-drug therapy improves kidney graft survival.
Kaden J; May G; Müller P; Groth J; Strobelt V; Eger E; Wohlfahrt L
Transplant Proc; 1995 Feb; 27(1):1060-1. PubMed ID: 7878804
[No Abstract] [Full Text] [Related]
7. Initiation of ALG pretransplant reduces the incidence of delayed renal allograft function.
Hong JH; Sumrani N; Cacciarelli TV; Distant D; Sommer BG
Transplant Proc; 1993 Feb; 25(1 Pt 1):581-2. PubMed ID: 8438423
[No Abstract] [Full Text] [Related]
8. Case studies: conversion from Sandimmune to Neoral in stable renal allograft recipients.
Roth D; Miller J
Transplant Proc; 1996 Aug; 28(4):2219-20; discussion 2218. PubMed ID: 8769204
[No Abstract] [Full Text] [Related]
9. Comparison of Neoral and Sandimmune preparations in renal transplant patients--improved pharmacokinetics with neoral.
Warrens AN; Salama A; Waters JB; Lechler RI
Transplant Proc; 1996 Aug; 28(4):2169-70. PubMed ID: 8769190
[No Abstract] [Full Text] [Related]
10. Mycophenolate mofetil versus azathioprine in simultaneous pancreas-kidney transplant recipients on cyclosporine.
Fabrega AJ; Corwin CL; Hunsicker L
Transplant Proc; 1998 Jun; 30(4):1562-3. PubMed ID: 9636634
[No Abstract] [Full Text] [Related]
11. Causes of long-term renal allograft failure: no chronic rejection at three years.
Shen GK; Isenberg AL; Singh TP; Hahn A; Conti DJ
Transplant Proc; 1998 Jun; 30(4):1205-6. PubMed ID: 9636489
[No Abstract] [Full Text] [Related]
12. Quantitation of immunosuppression by flow cytometric measurement of the capacity of T cells for interleukin-2 production.
van den Berg AP; Twilhaar WN; Mesander G; van Son WJ; van der Bij W; Klompmaker IJ; Slooff MJ; The TH; de Leij LH
Transplantation; 1998 Apr; 65(8):1066-71. PubMed ID: 9583867
[TBL] [Abstract][Full Text] [Related]
13. Immunity in maintenance immunosuppression with and without cyclosporine in long-term kidney transplant recipients.
Yamashita M; Aikawa A
Transplant Proc; 2000 Nov; 32(7):1768-72. PubMed ID: 11119927
[No Abstract] [Full Text] [Related]
14. One year results of preoperative single bolus ATG-Fresenius induction therapy in sensitized renal transplant recipients.
Wang D; Chen JH; Wu WZ; Yang SL; Wu GJ; Wang H; Tan JM
Transplant Proc; 2007; 39(1):69-72. PubMed ID: 17275476
[TBL] [Abstract][Full Text] [Related]
15. Bolus anti-thymocyte globulin induction in renal transplant recipients: a comparison with conventional ATG or anti-interleukin-2 receptor antibody induction.
Nampoory MR; Abdulhalim M; Johny KV; Al-Jawad Donia FA; Nair MP; Said T; Homoud H; Samhan M; Al-Mousawi M
Transplant Proc; 2002 Nov; 34(7):2916-9. PubMed ID: 12431656
[No Abstract] [Full Text] [Related]
16. Donor-specific transfusion under the new cyclosporine A formulation Consupren versus azathioprine, Imuran.
Kamel G; Stephan A; Masri MA; Barbari A; Kelany H; Younan F; Karam A
Transplant Proc; 1997 Nov; 29(7):2960-1. PubMed ID: 9365629
[No Abstract] [Full Text] [Related]
17. Low dose antithymocyte globulins in renal transplantation: daily versus intermittent administration based on T-cell monitoring.
Djamali A; Turc-Baron C; Portales P; Leverson G; Chong G; Clot J; Mourad G
Transplantation; 2000 Mar; 69(5):799-805. PubMed ID: 10755529
[TBL] [Abstract][Full Text] [Related]
18. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
Løkkegaard H; Asmundsson P; Clausen P; Dieperink H; Hansen JM; Heaf J; Jensen SB; Kornerup HJ; Madsen S; Pedersen EB; Poulsen JV; Rasmussen K
Transplant Proc; 1996 Aug; 28(4):2199-201. PubMed ID: 8769199
[No Abstract] [Full Text] [Related]
19. Role of immunosuppressive drugs in the development of tissue-invasive cytomegalovirus infection in renal transplant recipients.
Kuypers DR; Evenepoel P; Maes BD; Coosemans W; Pirenne J; Vanrenterghem YF
Transplant Proc; 2002 Jun; 34(4):1164-70. PubMed ID: 12072305
[No Abstract] [Full Text] [Related]
20. Excellent long-term survival of low-risk, first renal allografts using cyclosporine/azathioprine double therapy.
Faull RJ; Bannister KM; Russ GR; Mathew TH; Clarkson AR
Transplant Proc; 1999; 31(1-2):1155-6. PubMed ID: 10083516
[No Abstract] [Full Text] [Related]
[Next] [New Search]
